Request Information

Auris Secures Additional Funding to Advance Platform

Nov 29 2018

Compelo


Auris was featured on Compelo, a online news publication covering medical devices, about additional funding received to advance the Monarch Platform.

Auris secured $220 million in equity financing under the financing round led by Partner Fund Management. Wellington Management, D1 Capital Partners, Senator Investment Group, Mithril Capital, Lux Capital and Viking Global Investors also participated in the round. These additional funds will be used to advance the commercialization of the Monarch Platform and develop the next generation of interventional technology in robotics. Auris has raised over $700 million to date in funding, including this recent addition.

Auris has already received FDA approval to use the Monarch Platform for diagnostic and therapeutic bronchoscopy procedures. The platform allows physicians to navigate the flexible bronchoscope to the periphery of the lung using a controller interface. The platform provides the physician with continuous bronchoscope vision, computer guidance, and very precise control throughout the procedure. This technology allows physicians to more accurately diagnose and treat small and hard-to-reach nodules in the periphery of the lung. Lung cancer is one of the top causes of cancer deaths across the world, and early diagnosis can lead to a better prognosis for patients.

This additional funding will help further Auris's plans to advance medical intervention by incorporating robotic, micro-instrumentation, endoscope design, sensing, and data science into a single platform, optimizing both physician capabilities and patient outcomes.

The article includes a quote from Auris Health CEO Dr. Frederic Moll, who said of the additional funding: "We are pleased with our progress in launching the Monarch Platform, which was initiated earlier this year. This funding will enable us to expand our commercialization efforts for endobronchial applications, and will also support our mission to pioneer the next era of medical intervention across a broader spectrum of procedures."

Read the Full Article on Compelo
Back to all News